Last reviewed · How we verify
Bromfenac 0.09 % Ophthalmic Solution
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis in the eye. Used for Postoperative inflammation and pain following ocular surgery, Reduction of ocular inflammation and pain in patients undergoing cataract surgery.
At a glance
| Generic name | Bromfenac 0.09 % Ophthalmic Solution |
|---|---|
| Also known as | Yellox, Bromfenac 0.09 % |
| Sponsor | Azienda USL Reggio Emilia - IRCCS |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
By blocking COX-1 and COX-2 enzymes, bromfenac decreases production of inflammatory prostaglandins in ocular tissues. This reduces inflammation, pain, and photophobia associated with ocular surgery and other inflammatory conditions of the eye. The ophthalmic solution formulation allows direct delivery to the anterior segment.
Approved indications
- Postoperative inflammation and pain following ocular surgery
- Reduction of ocular inflammation and pain in patients undergoing cataract surgery
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Headache
- Corneal adverse events (rare)
Key clinical trials
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Bromfenac Versus Dexamethasone After Cataract Surgery (PHASE4)
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. (PHASE4)
- Control of Pain in Intravitreal Injections Using Topical NSAIDs (PHASE4)
- Comparison of Treatments in Diabetic Macular Edema (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: